CD4 and hepatocellular carcinoma: In our study, we surveyed two cardinal T-cell components of anticancer immunity: the effector, immune-exhausted cytotoxic branch (CD8+/PD-1+) and the T-reg compartment (CD4+/FOXP3+), both of which are linked with poorer prognosis in HCC [15].